Business Description
![UroGen Pharma Ltd UroGen Pharma Ltd logo](https://static.gurufocus.com/logos/0C0000B8SW.png?14)
UroGen Pharma Ltd
SIC : 2834
ISIN : IL0011407140
Description
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.45 | |||||
Equity-to-Asset | 0.11 | |||||
Debt-to-Equity | 3.24 | |||||
Debt-to-EBITDA | -1.04 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -2.06 | |||||
Beneish M-Score | -2.68 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 74.3 | |||||
3-Year EBITDA Growth Rate | 20.8 | |||||
3-Year EPS without NRI Growth Rate | 20.5 | |||||
3-Year FCF Growth Rate | 18.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 28.37 | |||||
Future 3-5Y Total Revenue Growth Rate | 47.16 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 26.05 | |||||
9-Day RSI | 32.1 | |||||
14-Day RSI | 36.85 | |||||
6-1 Month Momentum % | -1.94 | |||||
12-1 Month Momentum % | -17.39 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 8.15 | |||||
Quick Ratio | 7.93 | |||||
Cash Ratio | 7.04 | |||||
Days Inventory | 257.31 | |||||
Days Sales Outstanding | 64.72 | |||||
Days Payable | 252.57 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -13.6 | |||||
Shareholder Yield % | -23.82 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 89.87 | |||||
Operating Margin % | -93.74 | |||||
Net Margin % | -133.61 | |||||
FCF Margin % | -101.06 | |||||
ROA % | -59.8 | |||||
ROIC % | -332.91 | |||||
ROC (Joel Greenblatt) % | -1229.59 | |||||
ROCE % | -59.81 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 5.78 | |||||
PB Ratio | 19.24 | |||||
Price-to-Tangible-Book | 19.24 | |||||
EV-to-EBIT | -4.71 | |||||
EV-to-EBITDA | -4.78 | |||||
EV-to-Revenue | 5.33 | |||||
EV-to-Forward-Revenue | 4.92 | |||||
EV-to-FCF | -5.28 | |||||
Price-to-Net-Current-Asset-Value | 21.17 | |||||
Earnings Yield (Greenblatt) % | -21.23 | |||||
FCF Yield % | -14.41 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
UroGen Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 78.691 | ||
EPS (TTM) (€) | -2.979 | ||
Beta | 2.8 | ||
Volatility % | 57.03 | ||
14-Day RSI | 36.85 | ||
14-Day ATR (€) | 0.389794 | ||
20-Day SMA (€) | 13.545 | ||
12-1 Month Momentum % | -17.39 | ||
52-Week Range (€) | 9.95 - 17.8 | ||
Shares Outstanding (Mil) | 42.11 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
UroGen Pharma Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
UroGen Pharma Ltd Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
UroGen Pharma Ltd Frequently Asked Questions
What is UroGen Pharma Ltd(STU:UR8)'s stock price today?
The current price of STU:UR8 is €12.70. The 52 week high of STU:UR8 is €17.80 and 52 week low is €9.95.
When is next earnings date of UroGen Pharma Ltd(STU:UR8)?
The next earnings date of UroGen Pharma Ltd(STU:UR8) is 2024-11-14 Est..
Does UroGen Pharma Ltd(STU:UR8) pay dividends? If so, how much?
UroGen Pharma Ltd(STU:UR8) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |